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Muscular dystrophies are a group of diseases that primar- 
ily affect skeletal muscle and are characterized by progres- 
sive muscle wasting and weakness. Although these dis- 
eases have been clinically recognized for a number of 
years, genetic defects in a number of muscular dystro- 
phies have only recently been identified. One of the most 
important advances in understanding the molecular genet- 
ics of neuromuscular diseases has been the cloning of the 
gene encoding dystrophin, the protein absent in muscle of 
Duchenne muscular dystrophy (DMD) patients. In the last 
few years, the role of dystrophin in skeletal muscle has 
been studied, and several dystrophin-associated proteins 
(DAPs) have been identified. Components of the dys- 
trophin-glycoprotein complex are now being character- 
ized, and evidence is beginning to indicate that proteins 
of this complex may be responsible for other forms of mus- 
cular dystrophy. The present review focuses on the molec- 
ular basis of three muscular dystrophies (DMD, severe child- 
hood autosomal recessive muscular dystrophy [SCARMD], 
and congenital muscular dystrophy [CMD]) that may be 
caused by disruptions in the dystrophin-glycoprotein com- 
plex, which normally links the subsarcolemmal cytoskele- 
ton to the extracellular matrix in skeletal muscle. 
DMD and Becket Muscular Dystrophy 
DMD and Becker muscular dystrephy (BMD) are X-linked 
recessive diseases that are caused by mutations in the 
DMD gene (reviewed by Hoffman and Kunkel, 1989). The 
DMD gene is an extremely large and complex gene con- 
taining at least five promoters, which regulate the expres- 
sion of three isoforms of dystrophin (-427 kDa) and two 
smaller proteins of 71 kDa (DP71) and 116 kDa (DPl16) 
(reviewed by Ahn and Kunkel, 1993). The 427 kDa isoform 
of dystrophin, expressed in muscle and brain, consists 
of four structurally distinct domains (the amino-terminal 
actin-binding domain, the large spectrin-like rod domain, 
the cysteine-rich domain, and the unique carboxy-terminal 
domain). Dystrophin is localized to the sarcolemma in nor- 
mal skeletal muscle, but is completely absent in muscle 
from DMD patients and in two animal models for DMD, 
mdx mice and grind dogs. Mutant forms of dystrophin that 
lack the cysteine-rich and carboxy-terminal domains or 
the amino-terminal actin-binding domain also result in a 
DMD phenotype. The milder BMD phenotype generally 
results from in-frame mutations that result in expression 
of dystrophin of lower abundance, smaller size, or both. 
The overall importance of the amino- and carboxy-terminal 
(cysteine-rich and carboxyl) domains of dystrophin is sup- 
ported by the existence of mild cases of BMD in which a 
shorter dystrophin molecule is expressed that preserves 
these domains. 
Dystrophin-Glycoprotein Complex: A Novel 
Laminin Receptor Linking the Cytoskeleton 
and Extracellular Matrix 
Based on homologies to ~-actinin and spectrin and on its 
localization to the sarcolemma, dystrophin was proposed 
to be a membrane cytoskeletal protein (Hoffman and Kun- 
kel, 1989). However, the exact function of dystrophin in 
skeletal muscle was not revealed by its primary structure. 
Initial biochemical experiments demonstrated atight asso- 
ciation of dystrophin with sarcolemmal glycoproteins and 
suggested that dystrophin was involved in the anchoring 
of sarcolemmal proteins to the underlying cytoskeleton 
(Campbell and Kahl, 1989). Subsequently, a dystrophin- 
glycoprotein complex was purified by sucrose gradient 
centrifugation in the form of a large ( -  18S) complex and 
was shown to contain several novel sarcolemmal protein 
and glycoprotein components (Ervasti et al., 1990; Yo- 
shida and Ozawa, 1990) (Table 1). 
Structural and functional characterization of dystrophin 
and the DAPs is now giving clues to the overall membrane 
organization (Figure 1) and to the role of the dystrophin- 
glycoprotein complex in skeletal muscle (reviewed by Mat- 
sumura and Campbell, 1994; Tinsley et al., 1994). Table 
1 summarizes the current knowledge of the components 
of the dystrophin-glycoprotein complex. Present outside 
of the muscle cell, ~-dystroglycan (also called 156 DAG, 
for dystrophin-associated glycoprotein) links the sarco- 
lemmal membrane to the extracellular matrix by binding 
the G domain of merosin (muscle isoform of laminin) with 
high affinity in a calcium-dependent manner (Ibraghimov- 
Beskrovnaya et al., 1992; Ervasti and Campbell, 1993; 
Gee et al., 1993; Sunada et al., 1994). The glycoprotein 
complex links ~-dystroglycan to the sarcolemma and is 
composed of the five integral membrane proteins: adhalin 
(50 DAG), a 43 kDa glycoprotein doublet (13-dystroglycan 
and a novel 43 kDa glycoprotein [43 DAG, also known as 
A3b]), a 35 kDa glycoprotein (35 DAG), and a 25 kDa pro- 
tein (25 DAP) (Ervasti et al., 1990; Yoshida and Ozawa, 
1990; Ibraghimov-Beskrovnaya etal., 1992; Suzuki et al., 
1994). Finally, dystrophin links the subsarcolemmal cy- 
toskeleton to the sarcolemma by binding F-actin through 
its amino-terminal domain (Hemmings et al., 1992) and 
the glycoprotein complex through its carboxy-terminal do- 
mains (Suzuki et al., 1994). The syntrophin triplet (59 DAP) 
also directly associates with the carboxy-terminal domain 
of dystrophin (Suzuki et al., 1994). 
The characterization of the dystrophin-glycoprotein 
complex has provided considerable support for the sche- 
matic model shown in Figure 2. In this model, dystrophin 
is the cytoskeletal link between the subsarcolemmal actin- 
cytoskeleton and the glycoprotein complex, and dystrogly- 
can is the extracellular link between the glycoprotein com- 
plex and merosin. The overall organization of the complex 
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Table 1. Components of the Dystrophin-Glycoprotein Complex 
Location Protein Other Name(s) Size (kDa) Gene Location Function 
Extracellular Matrix Laminin ct2 chain Merosin 400 6p22-23 
Sarcolemma 
Extracellular 156 DAG 156 3p21 
Transmembrane 
Intracellular 
Cytoskeleton 
~-Dystroglycan 
~-Dystroglycan 43 DAG, A3a 43 
Adhalin 50 DAG, A2, SL50 50 
43 DAG A3b 43 
35 DAG A4 35 
25 DAP A5 25 
~-Syntrophin 59 DAP1, Syn 1 58 
J~l-Syntrophin 59 DAP2, Syn 2 59 
~2-Syntrophin 59 DAP3, Syn 3 60 
Dystrophin 427 
3p21 
17q21 
Un known 
Unknown 
Unknown 
20ql 1 
16 
8q23-24 
Xp21 
Basal lamina component that binds 
~-dystroglycan 
Binds laminin-2 and is involved in 
linkage of dystrophin to laminin-2 
Binds dystrophin and is involved in 
linkage to laminin-2 
Unknown ") 
Unknown 
Unknown ~ May form a subcompiex 
Unknown J
Binds dystrophin/utrophin 
Binds dystrophin/utrophin 
Binds dystrophin/utrophin 
Membrane cytoskeletal protein linking 
transmembrane glycoprotein 
complex to F-actin 
Reviewed by Matsumura nd Campbell, 1994; Tinsley et al., 1994. 
and the high density of dystrophin in the sarcolemma 
strongly suggest that this complex has a structural role in 
skeletal muscle. The linkage between the cytoskeleton 
and the extracellular matrix through dystroglycan likely 
provides an important mechanism of anchoring muscle 
cells to the extracellular matrix. This attachment may sta- 
bilize the membrane and protect he sarcolemma from the 
stresses that develop during muscle contraction. 
Dystrophin 
Sarcolemma Membrane 
mphins 
Figure 1. Membrane Organization of the Dystrophin-Glycoprotein 
Complex 
Merosin, a component of the extracellular matrix, binds to ~-dystro- 
glycan, which is linked to the sarcolemmal g ycoprotein complex that 
contains adhalin (50 DAG), 13-dystroglycan, 43DAG (also known as 
A3b), a 35 kDa glycoprotein (35 DAG), and a 25 kDa protein (25 DAP). 
The membrane glycoprotein complex is linked to the cysteine-rich 
domain of dystrophin by ~-dystroglycan, and the amino-terminal (N) 
domain of dystrophin binds the actin-cytoskeleton. Syntrophins are 
bound to the carboxy-terminal (C)domain of dystrophin. 
Molecular Pathogenesis of DMD 
How does the absence of dystrophin lead to muscle cell 
necrosis in DMD? Based on current understanding of the 
function of the dystrophin-glycoprotein complex, the ab- 
sence of dystrophin would result in the disruption of the 
linkage between the subsarcolernmal cytoskeleton and 
the glycoprotein complex in muscle of patients with DMD 
(Figure 2). This, in turn, may render the sarcolemma sus- 
ceptible to damage from muscle contraction and thus lead 
to muscle cell necrosis. Support for this mechanism of 
pathogenesis comes from the fact that dystrophin-defi- 
cient muscle fibers of the mdx mouse exhibit an increased 
susceptibility to contraction-induced sarcolemmal ruptu re 
(Petrof et al., 1993). 
Immunohistochemistry studies have also revealed a 
dramatic reduction in all of the DAPs in the sarcolemma 
of DMD muscle compared with normal muscle and muscle 
from a variety of other neuromuscular diseases (reviewed 
by Matsumura and Campbell, 1994). A similar reduction in 
DAPs was observed in mdx mice, which have a nonsense 
mutation in the dystrophin gene that results in the absence 
of dystrophin in mdx muscle. The specificity of the loss 
of the DAPs can be seen in DMD carriers, where the only 
fibers positive for dystrophin are also positive for the DAPs. 
In BMD there is a mild reduction of the DAPs, consistent 
with a reduced content of dystrophin. In DMD patients 
lacking the cysteine-rich and carboxy-terminal domains of 
dystrophin, all of the DAPs are drastically reduced in the 
sarcolemma despite proper localization of the truncated 
dystrophin to the sarcolemma. Therefore, the absence of 
dystrophin or the lack of its carboxy-terminal domains can 
lead to a reduction in all of the DAPs in the sarcolemrna. 
Autosomal Recessive Muscular Dystrophy 
Studies concerning the structure and function of the dys- 
trophin-glycoprotein complex raised the intriguing possi- 
bility that a primary deficiency in a DAP could be responsi- 
ble for an autosomal recessive muscular dystrophy with 
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Human 
Diseases 
CMD 
(rnerosin-deficient) 
SCARMD 
(adhalin-deficient) 
( dystrophin 
C-tarm/Cys-dch deletions 
DMD I dystrophin-deficlent 
/ dvstrophin 
~-~'~rminal mutations --~ 
Involvement of the Dystrophin-Glycoprotein 
Complex in Muscular Dystrophies 
Animal 
Models 
I Extraoellular Matrix ] 
4-- dy ~ mouse 
(merosln deletion) 
Merosin ._  dy mouse (merosin-deficient) 
I ° -Dystr°glyoan I
~ Glycoprotein Complex~ ~BIO 14.6 Hamster  (adhalin-deficient) 
$ 
t Dystrophin ] 
[ F-Aotin Cytoskeleton ]
mdxmouse 
(dystrophin-deflcient) 
DP71 transgenic 
mdx mouse 
Figure 2. Involvement ofthe Dystrophin-Gly- 
coprotein Complex in Various Human and Ani- 
mal Muscular Dystrophies 
Interactions between the various components 
of the dystrophin-glycoprotein complex are il- 
lustrated by double-headed arrows. Sites of 
disruption of the dystrophin-glycoprotein com- 
plex in various diseases are illustrated by sin- 
gle-headed arrows. In some cases, a genetic 
defect has been found in a component of the 
dystrophin-glycoprotein complex, whereas in 
others only a biochemical deficiency has been 
noted to date (see text for details). The BIO 
14.6 cardiomyopathic amster, not mentioned 
in the text, is a possible model of one form of 
autosomal recessive muscular dystrophy since 
skeletal and cardiac muscle from this hamster 
are deficient in adhalin; however, the underly- 
ing genetic defect is not known. 
a DMD-like phenotype. Analysis o~.~ muscle from autosomal 
recessive muscular dystrophy revealed a specific absence 
of the adhalin protein in SCARMD patients (Matsumura et 
al., 1992). SCARMD resembles DMD or BMD, but affects 
females and males with equal frequency. SCARMD was 
first identified in Tunisia and has since been found in other 
populations. In several North African families, SCARMD 
has been linked to markers in the pericentromeric region 
of chromosome 13q, but the affected gene has not yet 
been identified (Ben Othmane et al., 1992). The adhalin 
gene was mapped to chromosome 17q21, excluding the 
gene from involvement in 13q-linked SCARMD (McNally 
et al., 1994; Roberds et al., 1994). However, the adhalin 
gene was linked to autosomal recessive muscular dystro- 
phy in one large family, and missense mutations were 
identified within the gene of four affected children in this 
family (Roberds et al., 1994). 
CMD with Merosin Deficiency 
Demonstration that laminin is the native ligand for ~-dys- 
troglycan (Ibraghimov-Beskrovnaya et l., 1992) prompted 
investigation of whether one of the laminin subunits could 
be involved in other forms of autosomal recessive muscu- 
lar dystrophy. A specific absence of merosin, the laminin 
a2 chain, was observed in 13 patients affected by a classi- 
cal non-Fukuyama type of CMD (Tome et al., 1994).CMD 
is a heterogeneous group of severe autosomal recessive 
neuromuscular disease with early clinical onset. Manifes- 
tations of CMD are evident at birth or in the first few months 
of life and consist of muscle weakness and hypotonia, 
delayed motor milestones, severe and early contractures, 
and often joint deformities. The absence of merosin in 
muscle of CMD patients may lead to a disruption of the 
linkage between the sarcolemma membrane and the ex- 
tracellular matrix. Recently, four merosin-negative CMD 
families have been shown by homozygosity mapping to 
be linked to chromosome 6q2 near the merosin gene (Hil- 
laire et al., 1994). However, mutations in the merosin gene 
have yet to be identified. 
An animal model for CMD with merosin deficiency is the 
dystrophia muscularis (dy) mouse, which is characterized 
by muscular degeneration and developmental dysmyeli- 
nation of peripheral nerve. The mouse c~2 chain gene 
Lama2 maps to the same region of mouse chromosome 
10 to which the dy locus has been mapped (Sunada et 
al., 1994). Analysis of merosin expression in dystrophic dy 
mice revealed a specific deficiency of merosin in skeletal 
muscle, cardiac muscle, and peripheral nerve (Arahata et 
al., 1993; Sunada et al., 1994; Xu et al., 1994). Recently, 
Xu et al. (1994) located a mutation in the merosin gene 
of the dy 2J mouse (allelic for dy). This mutation results in 
the expression of a truncated c~2 chain lacking a portion 
of domain VI that is involved in laminin self-aggregation. 
Genetic Basis of Other Muscular Dystrophies 
Table 2 lists the various human muscular dystrophies and 
their gene locations (reviewed by McKusick, 1994). To 
date, ten forms of muscular dystrophy have been charac- 
terized at the chromosomal evel; in three of these dis- 
eases, mutations in specific genes have been identified 
and the protein products are now being studied. In addi- 
tion, there are several animal models that have defects 
in the genes responsible for the human muscular dystro- 
phies. Emerin, the protein product of the Emery-Dreifuss 
muscular dystrophy gene, has only recently been charac- 
terized. Emerin is a 254 amino acid protein with one trans- 
membrane spanning domain whose function is not known. 
Fukuyama-type CMD has been localized to chromosome 
9q31-33, but the gene product for this form of muscular 
dystrophy is unknown. Two forms of autosomal recessive 
limb-girdle muscular dystrophy have been linked to chro- 
mosome 15q and to chromosome 2p. There are two major 
autosomal dominant muscular dystrophies: facioscapulo- 
humeral and autosomal dominant limb-girdle muscular 
dystrophies, which have been linked to chromosome 4q35 
and chromosome 5q, respectively. The myd mouse is a 
possible animal model for facioscapulohumeral dys- 
trophy. 
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Table 2. Molecular Genetics of Muscular Dystrophies 
Muscular Dystrophy Symbol MIM" Gene Location 
X-linked recessive 
DuchennelBecker DMD/BMD 310200 Xp21 
Emery-Dreifuss EDMD 310300 Xq28 
Autosomal recessive 
Limb-girdle LG M D2A 253600 15q 
LGM D2B 253600 2p 
SCARM D LG M D2C 253700 13q 12 
LGM D2D 253700 17q21 
Congenital (merosin deficient) CMD 156225 6q2 
Fukuyama-type congenital FCMD 253800 9q31-33 
Autosomal Dominant 
Facioscapulohumeral FSHD 158900 4q35 
Limb-girdle LGMD1A 159000 5q 
Animal Model Protein Product 
mdx mouse Dystrophin 
grmd dog 
-- Emerin 
- Unknown 
-- Unknown 
BIO 14.6 hamster? Unknown 
-- Adhalin 
dy and dy =J mice Merosin? 
-- Unknown 
myd mouse? Unknown 
-- Unknown 
Data from McKusick, 1994; Bushby and Beckmann, 1995. 
"Reference number in McKusick, 1994. 
Conclusion 
The involvement of the dystrophin-glycoprotein complex 
in the pathogenesis of three human muscular dystrophies 
is illustrated in Figure 2. According to the hypothesis pre- 
sented in this review, the dystrophin-glycoprotein com- 
plex is the major mechanism of attachment between the 
cytoskeleton and extracellular matrix in skeletal muscle. 
Disruption of this linkage likely leads to sarcolemmal insta- 
bility and muscle cell necrosis. Biochemical deficiencies in 
components of the complex have been observed in three 
forms of muscular dystrophy: DMD (dystrophin deficient), 
SCARMD (adhalin deficient), and one form of CMD (me- 
rosin deficient). DMD patients are deficient in dystrophin 
owing to mutations in the dystrophin gene. SCARMD pa- 
tients in one family were found to carry a mutation in the 
adhalin gene. Although the primary defect in merosin- 
deficient CMD patients has been gentically linked to a 
region of the chromosome near the merosin gene, muta- 
tions in the merosin gene have not yet been identified. 
The importance of sites of interaction between individual 
components of the complex can be seen in rare DMD 
cases and in several animal models. For example, the 
interaction of the carboxyl terminus of dystrophin with the 
glycoprotein complex is essential since patients that lack 
this region have a DMD phenotype. The linkage of dys- 
trophin to the actin-cytoskeleton is also crucial since pa- 
tients with amino-terminal dystrophin mutations have a 
severe phenotype. In addition, DP71 transgenic mdx mice 
(Cox et al., 1994; Greenberg et al., 1994) have a normal 
glycoprotein complex, but lack the required interaction 
with the actin-cytoskeleton and thus have a dystrophic 
phenotype. The recently described dy 2J mouse (Xu et al., 
1994), which has a deletion in merosin, reveals the impor- 
tance of the interaction of merosin with the other compo- 
nents of the extracellular matrix. Finally, the studies of the 
pathogenesis of these three forms of muscular dystrophy 
strongly suggest that gene therapy for these diseases will 
only be effective if the linkage between the cytoskeleton 
and the extracellular matrix is restored in skeletal muscle. 
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